We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Plasmodium falciparum

Most attempts at developing a vaccine for malaria — a disease that kills two million people a year — have targeted proteins that make up the malaria parasite, Plasmodium falciparum.

But a study reported in this week's journal Nature suggests that a more successful approach might be to target the toxins released by the parasite.

Louis Schofield of the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia and colleagues found that mice immunised against the GPI toxin were protected against many of the signs of malaria.

These results strongly suggest that GPI is responsible for some symptoms of malaria in humans, and that an anti-toxic vaccine could therefore be effective against malaria, the researchers say.

Link to Nature research paper by Schofield et al

© SciDev.Net 2002

Photo credit: WHO/TDR/Taylor-Robinson

Related topics